Study-context terms explain dose, route, formulation, timing, and endpoint.
Dictionary / Study context
Route of administration
How oral, inhaled, topical, sublingual, and other routes change interpretation.
Study contextterm category
7related public pages
editorial navigationdefinition status
draftreview status
70exact evidence rows
59exact source links
104nearby evidence rows
104nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Route of administration explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
59 direct sources linked to approved workbench claims. PubMed 39204082
104 nearby evidence rows and 104 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Route of administration is used in this encyclopedia as a study context term. How oral, inhaled, topical, sublingual, and other routes change interpretation.
Study-context terms explain the conditions around a source: route, dose, formulation, timing, population, model, duration, and endpoint.
Also searched as: inhaled, oral, route, sublingual, topical.
Evidence Guardrail
How to read it without overreaching
Study context is the difference between a useful evidence row and an overread claim. Keep this term attached to the exact source, product, model, timing, and endpoint wherever possible.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 39204082
Distinct source records under those exact rows. PubMed 39204082
Source-backed public pages where this vocabulary is likely useful. Open related page
Evidence rows available on those related public pages. Open related page
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 39204082
- Open related pages.Use nearby pages for broader source-backed context. Related page
- Keep the boundary.Study context changes what a source can support, so keep it attached to the row.
Exact Evidence Rows
Approved source-backed rows linked to this term
70 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
21 exact rows / 16 sources
Evidence row 4 / uses term
CBN decreases Overall sleep disturbance.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 5 / uses term
CBN no detected effect on Side effect frequency.
preliminary human / low confidence.
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN for Improving Sleep PubMed 39204082
Claim or source metadata contains an explicit term marker.
Evidence row 6 / uses term
CBN no detected effect on Wake after sleep onset.
preliminary human / moderate confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 15 / uses term
CBN associated with Adverse events.
preliminary human / low confidence.
Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial PubMed 41698831
Claim or source metadata contains an explicit term marker.
Evidence row 28 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PubMed 38797087
Claim or source metadata contains an explicit term marker.
Evidence row 60 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial. PubMed 39505200
Claim or source metadata contains an explicit term marker.
Evidence row 62 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 233 / uses term
THC studied for Cannabinoids and nausea/vomiting research outcomes.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 368 / uses term
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
preliminary human / very_low confidence.
Observed Impact of Long-Term Consumption of Oral Cannabidiol on Liver Function in Healthy Adults. PubMed 34918948
Claim or source metadata contains an explicit term marker.
Evidence row 398 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. PubMed 31793418
Claim or source metadata contains an explicit term marker.
Evidence row 401 / uses term
CBD studied for Pain-related outcomes.
preliminary human / very_low confidence.
Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. PubMed 36571471
Claim or source metadata contains an explicit term marker.
Evidence row 409 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Claim or source metadata contains an explicit term marker.
Evidence row 414 / uses term
CBD studied for Sleep.
preliminary human / very_low confidence.
Evaluating possible 'next day' impairment in insomnia patients administered an oral medicinal cannabis product by night: a pilot randomized controlled trial. PubMed 38758300
Claim or source metadata contains an explicit term marker.
Evidence row 450 / uses term
THC studied for Cardiovascular risk.
preliminary human / very_low confidence.
The effects of combinations of intranasal cocaine, smoked marijuana, and task performance on heart rate and blood pressure. PubMed 2162543
Claim or source metadata contains an explicit term marker.
Evidence row 469 / uses term
THC studied for Cognition and memory.
preliminary human / very_low confidence.
Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. PubMed 12373420
Claim or source metadata contains an explicit term marker.
Evidence row 482 / uses term
THC studied for Nausea and vomiting.
preliminary human / very_low confidence.
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial. PubMed 39151115
Claim or source metadata contains an explicit term marker.
Evidence row 500 / uses term
THC studied for Sleep.
preliminary human / very_low confidence.
Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial. PubMed 40631525
Claim or source metadata contains an explicit term marker.
Evidence row 612 / uses term
CBG studied for Skin and inflammatory dermatology.
preliminary human / very_low confidence.
Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. PubMed 40124934
Claim or source metadata contains an explicit term marker.
Evidence row 717 / uses term
CBC studied for Skin and inflammatory dermatology.
preliminary human / very_low confidence.
Broad-spectrum bactericidal synergy of silver-cannabichromene-cannabigerol triple combinations against healthcare-associated pathogens. PubMed 41983582
Claim or source metadata contains an explicit term marker.
Evidence row 745 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preliminary human / very_low confidence.
A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants. PubMed 37721990
Claim or source metadata contains an explicit term marker.
Evidence row 1173 / uses term
LEA studied for LEA biology, metabolism, physiology, or safety-relevant mechanisms.
preliminary human / very_low confidence.
Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males. PubMed 29778785
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
22 exact rows / 20 sources
Evidence row 141 / uses term
CBDA studied for nausea-related or inflammation-related outcomes.
insufficient / very_low confidence.
Serum cannabidiol, tetrahydrocannabinol (THC), and their native acid derivatives after transdermal application of a low-THC Cannabis sativa extract in beagles. PubMed 32735381
Claim or source metadata contains an explicit term marker.
Evidence row 226 / uses term
CBD modulates endocannabinoid enzyme activity or metabolic mechanisms.
insufficient / very_low confidence.
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise. PubMed 39630203
Claim or source metadata contains an explicit term marker.
Evidence row 333 / uses term
THC studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Acid-Catalyzed Conversion of Cannabidiol to Tetrahydrocannabinols: En Route to Demystifying Manufacturing Processes and Controlling the Reaction Outcomes. PubMed 40250991
Claim or source metadata contains an explicit term marker.
Evidence row 340 / uses term
CBD studied for safety, risk, adverse-event, or formulation-specific concerns.
insufficient / very_low confidence.
Cannabidiol in Skin Health: A Comprehensive Review of Topical Applications in Dermatology and Cosmetic Science. PubMed 41008526
Claim or source metadata contains an explicit term marker.
Evidence row 463 / uses term
THC studied for Cognition and memory.
insufficient / very_low confidence.
Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol. PubMed 31407943
Claim or source metadata contains an explicit term marker.
Evidence row 491 / uses term
THC studied for Appetite and metabolic outcomes.
insufficient / very_low confidence.
Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. PubMed 29670357
Claim or source metadata contains an explicit term marker.
Evidence row 609 / uses term
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota. PubMed 36768709
Claim or source metadata contains an explicit term marker.
Evidence row 615 / uses term
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. PubMed 38889235
Claim or source metadata contains an explicit term marker.
Evidence row 618 / uses term
CBG studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Design, synthesis, and biological profiling of fluorinated cannabidiol and cannabigerol derivatives as promising therapeutic agents. PubMed 41645347
Claim or source metadata contains an explicit term marker.
Evidence row 701 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
The Potential of Cannabichromene (CBC) as a Therapeutic Agent. PubMed 38777605
Claim or source metadata contains an explicit term marker.
Evidence row 702 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. PubMed 37630401
Claim or source metadata contains an explicit term marker.
Evidence row 705 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion. PubMed 38885660
Claim or source metadata contains an explicit term marker.
Evidence row 706 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation. PubMed 38889235
Claim or source metadata contains an explicit term marker.
Evidence row 709 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabis-Based Phytocannabinoids: Overview, Mechanism of Action, Therapeutic Application, Production, and Affecting Environmental Factors. PubMed 39457041
Claim or source metadata contains an explicit term marker.
Evidence row 710 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against Streptococcus and Staphylococcus. PubMed 39596719
Claim or source metadata contains an explicit term marker.
Evidence row 714 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Geotemporospatial and causal inferential epidemiological overview and survey of USA cannabis, cannabidiol and cannabinoid genotoxicity expressed in cancer incidence 2003-2017: part 1 - continuous bivariate analysis. PubMed 35354487
Claim or source metadata contains an explicit term marker.
Evidence row 715 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Design and synthesis of amphiphilic cannabichromene derivatives with antimicrobial potential. PubMed 41202683
Claim or source metadata contains an explicit term marker.
Evidence row 716 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Targeting the antioxidant, antimicrobial and anti-inflammatory activity of non-psychotropic Cannabis sativa L.: a comparison with chemotype V. PubMed 41121423
Claim or source metadata contains an explicit term marker.
Evidence row 718 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Synthetic Pathways to Non-Psychotropic Phytocannabinoids as Promising Molecules to Develop Novel Antibiotics: A Review. PubMed 37514074
Claim or source metadata contains an explicit term marker.
Evidence row 719 / uses term
CBC studied for Skin and inflammatory dermatology.
insufficient / very_low confidence.
Spent Material Extractives from Hemp Hydrodistillation as an Underexplored Source of Antimicrobial Cannabinoids. PubMed 38927152
Claim or source metadata contains an explicit term marker.
Evidence row 1045 / uses term
CBD modulates TRPA1.
insufficient / very_low confidence.
Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. PubMed 35605018
Claim or source metadata contains an explicit term marker.
Evidence row 1057 / uses term
CBD modulates TRPM8.
insufficient / very_low confidence.
Systematic Review on Transdermal/Topical Cannabidiol Trials: A Reconsidered Way Forward. PubMed 35605018
Claim or source metadata contains an explicit term marker.
Evidence Group
Preclinical
9 exact rows / 6 sources
Evidence row 172 / uses term
Delta-8 THC studied for safety, adverse-event, impairment, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 191 / uses term
CBD studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
preclinical / very_low confidence.
Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring. PubMed 41840986
Claim or source metadata contains an explicit term marker.
Evidence row 223 / uses term
Cannabinoids studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Increased vulnerability to atrial and ventricular arrhythmias caused by different types of inhaled tobacco or marijuana products. PubMed 36603937
Claim or source metadata contains an explicit term marker.
Evidence row 607 / uses term
CBG studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 644 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence row 703 / uses term
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
Design, synthesis, and biological evaluation of membrane-active cannabichromene derivatives as potent antibacterial agents. PubMed 40580638
Claim or source metadata contains an explicit term marker.
Evidence row 704 / uses term
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
The antinociceptive activity and mechanism of action of cannabigerol. PubMed 36916438
Claim or source metadata contains an explicit term marker.
Evidence row 720 / uses term
CBC studied for Skin and inflammatory dermatology.
preclinical / very_low confidence.
Biological activity of cannabichromene, its homologs and isomers. PubMed 7298870
Claim or source metadata contains an explicit term marker.
Evidence row 744 / uses term
THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns.
preclinical / very_low confidence.
Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats. PubMed 37721989
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
18 exact rows / 17 sources
Evidence row 165 / uses term
CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PubMed 41822224
Claim or source metadata contains an explicit term marker.
Evidence row 562 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Claim or source metadata contains an explicit term marker.
Evidence row 606 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. PubMed 39596290
Claim or source metadata contains an explicit term marker.
Evidence row 608 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Targeting Vascular and Inflammatory Crosstalk: Cannabigerol as a Dual-Pathway Modulator in Rosacea. PubMed 40725084
Claim or source metadata contains an explicit term marker.
Evidence row 610 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. PubMed 35056807
Claim or source metadata contains an explicit term marker.
Evidence row 611 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway. PubMed 39851511
Claim or source metadata contains an explicit term marker.
Evidence row 613 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives. PubMed 37949940
Claim or source metadata contains an explicit term marker.
Evidence row 614 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Skin cells protection against UVA radiation - The comparison of various antioxidants and viability tests. PubMed 39647320
Claim or source metadata contains an explicit term marker.
Evidence row 616 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
The Anti-Inflammatory Action of Cannabigerol Accompanied by the Antioxidant Effect of 3-O-ethyl Ascorbic Acid in UVA-Irradiated Human Keratinocytes. PubMed 37652708
Claim or source metadata contains an explicit term marker.
Evidence row 617 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
A new cannabigerol derivative, LE-127/2, induces autophagy mediated cell death in human cutaneous melanoma cells. PubMed 39357769
Claim or source metadata contains an explicit term marker.
Evidence row 619 / uses term
CBG studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. PubMed 27094344
Claim or source metadata contains an explicit term marker.
Evidence row 651 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. PubMed 33134364
Claim or source metadata contains an explicit term marker.
Evidence row 700 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabinoids: Therapeutic Applications, Mechanisms, and Challenges in Modern Medicine. PubMed 42163693
Claim or source metadata contains an explicit term marker.
Evidence row 707 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. PubMed 27094344
Claim or source metadata contains an explicit term marker.
Evidence row 708 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. PubMed 39769302
Claim or source metadata contains an explicit term marker.
Evidence row 711 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes. PubMed 35628241
Claim or source metadata contains an explicit term marker.
Evidence row 712 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Cannabidiol and Minor Phytocannabinoids: A Preliminary Study to Assess Their Anti-Melanoma, Anti-Melanogenic, and Anti-Tyrosinase Properties. PubMed 37242431
Claim or source metadata contains an explicit term marker.
Evidence row 713 / uses term
CBC studied for Skin and inflammatory dermatology.
mechanistic or pharmacological / very_low confidence.
Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signaling Pathway. PubMed 36769042
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
safety
Product contamination and formulation risk
12 evidence rows / 12 sources
topic
Cannabinoid product contamination and formulation risk review
12 evidence rows / 12 sources
topic
CB1 receptor neurobehavioral/metabolic research summary
24 evidence rows / 24 sources
topic
CBC and skin/dermatology research summary
21 evidence rows / 21 sources
topic
CBG and skin/dermatology research summary
14 evidence rows / 14 sources
topic
CBC and neurobehavioral/neurogenesis outcomes review
12 evidence rows / 12 sources
topic
THCV and neurobehavioral/cognition outcomes review
9 evidence rows / 9 sources
Nearby Terms